Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi): Worried about the remainder of 2019 (?), think nine (9) factors…

May 20, 2019

Volatility, algorithms, sustainability … how are enrollments going as to population and is data from on-going trials being interpreted to render measurable and definitive outcomes? Add to the list, trend analysis, momentum’s magnitude, technicals and fundamentals – do they indicate expected pricing performance in 2019? Why spend time finding sector news and analytics … it’s all right here! 

Regenerative Medicine Earnings Scorecard - Q1/19 - to date

May 19, 2019

A scorecard of earnings of 45 covered  companies 41 so far: 2 acquired (AST, OSIR) 1 on acquisition hold - ONCE) and 1 set to be reversed (HSGX) ... The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"  

Regenerative Medicine Earnings Scorecard - Q4/18 and FY18 - to date

March 31, 2019

A scorecard of  (AKA) earnings of 45 covered  companies 44 out of 45 ...   The current LPS (loss per share) or net income, cash positions i.e. "runways" - it's a reflection of this universe's investing "status"  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.